Form 4: Bio-Rad Laboratories EVP Colleen Corey Reports Stock Option Grant

EVP Colleen Corey of Bio-Rad Laboratories reports the acquisition of stock options in a recent SEC Form 4 filing.

Summary

• Colleen Corey, EVP of Global Human Resources at Bio-Rad Laboratories, filed a Form 4 with the SEC.
• The filing reports the acquisition of 1,946 non-qualified stock options on March 3, 2025, at an exercise price of $256.45.
• These options vest over four years, at a rate of 25% per year on the anniversary of the grant date, and expire on March 3, 2035.
• Following the transaction, Corey directly owns 1,946 derivative securities.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. It doesn't inherently convey positive or negative sentiment, but rather reports a transaction.

Positives

• The grant of stock options aligns the executive's interests with those of the shareholders, incentivizing performance and value creation.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide investors with insights into the transactions of company executives and directors.

Stakeholder Impact

• The stock option grant could potentially incentivize Colleen Corey to improve company performance, benefiting shareholders.

Key Dates